

Fourth European Healthcare Policy Deciders Forum

Encouraging and Rewarding Innovation

Medicines Policy

Effectiveness and efficiency in resource allocation

February 17th – 18th, London

Uptake of innovative products across EU countries:

How to address existing discrepancies ?

Francis Arickx


National Institute for Health and Disability Insurance

Brussels, Belgium

...“Effective market access and utilisation vary strongly between and within Member States” ...

2008, High Level Pharmaceutical Forum

2009 sales per 100.000 inhabitants vs. number of available innovative medicines



Source: RIZIV/INAMI & IMS Health, 2010 (data on file)
Understanding and measuring pharmaceutical innovation across the European Union

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

REIMBURSE

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

ASAP

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

Innovation Availability Affordability

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

“Truly innovative medicines have a potential to lead to key improvements in health outcomes at the individual and the population levels. If, in addition, these medicines fill an unmet medical need, we propose to call them valuable.”

Belgian EU Presidency 2010


*Ministerial Conference on Innovation and Solidarity
September 2010*

Background report: “A call to make valuable innovative medicines accessible in the European Union. Recommendations for a coordinated action to stimulate, measure and valorise pharmaceutical innovation.”

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

INNOVATION and VALUE

Unmet Medical Needs
Patient and Societal perspective
Expectations
Offer Based versus Demand Driven
Priorities



Source: Gartner's Hype Cycle for Emerging Technologies 2010

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

INNOVATION and VALUE

Unmet Medical Needs
Patient and Societal perspective
Expectations
Offer Based versus Demand Driven
Priorities

AVAILABILITY

UMN and Priorities


Early Dialogue

Investment

Incentives

Fair Reward: IP and *Money for Value*


Locations of Drug Patent Inventors (Top Ten)



Source: Location of pharmaceutical innovation: 2000–2009
Yali Friedman
Nature Reviews Drug Discovery 9, 835-836 (November 2010)

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

Phase III and submission failures: 2007 - 2010



Source: Thomson Reuters Life Science Consulting, 2010

AFFORDABILITY


Cost and *Value for Money*

Sustainability

Innovative Financing Mechanisms

Solidarity


Total health expenditure per capita and GDP per capita, 2008



Source: OECD Health Data 2010; Eurostat Statistics Database; WHO National Health Accounts.

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

the Reality of Europe



Source: OECD Health Data 2010; Eurostat Statistics Database; WHO National Health Accounts.

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

AFFORDABILITY

Cost and *Value for Money*

Sustainability

Innovative Financing Mechanisms

Solidarity

2008, The High Level Pharmaceutical Forum:

... Member State authorities and stakeholders of the Pharmaceutical Forum should strengthen their efforts in ensuring **timely access** to **valuable innovations** and in ensuring access to medicines for all citizens...

...Member States are called upon to set **clear and common expectations** on what innovation they consider valuable and would **reward**. This will give companies a clear direction on healthcare **priorities** and indications on the evidence needed by authorities, while bringing authorities clarity on the mid- to long-term budget needs. Companies are called upon to deliver the innovative medicines **that society needs**. Cooperation with patient organisations should also be encouraged...

...National pricing and reimbursement policies should reflect and recognize these expectations and give a consistent reward to benefits considered valuable. National systems on pricing and reimbursement should therefore be well aligned with systems that assess the value of medicines....



Uptake of innovative products across EU countries:
How to address existing discrepancies ?

DG Industry and Entrepreneurship
Commissioner Tajani

Process on Corporate Responsibility in the field of Pharmaceuticals

three independent platforms :

Transparency and ethics in the sector

Access to medicines in Europe, in the context of pricing and reimbursement

Access to medicines in developing countries with a focus on Africa

DG Industry and Entrepreneurship
Commissioner Tajani

Process on Corporate Responsibility in the field of Pharmaceuticals

Access to medicines in Europe, in the context of pricing and reimbursement

A Mechanism of coordinated access to orphan medicinal products

Capacity building on contractual agreements for innovative medicines

Facilitating the supply in small countries

Promoting a good governance for non- prescription drugs

Market access for biosimilars

Uptake of innovative products across EU countries:
How to address existing discrepancies ?

conclusion

Availability Affordability Priorities Solidarity

Availability
Affordability
Priorities
Solidarity

thank you

Fourth European Healthcare Policy Deciders Forum

Encouraging and Rewarding Innovation

Medicines Policy

Effectiveness and efficiency in resource allocation

February 17th – 18th, London

Uptake of innovative products across EU countries: How to address existing discrepancies ?

Francis Arickx

National Institute for Health and Disability Insurance

Brussels, Belgium

Uptake of innovative products across EU countries:
How to address existing discrepancies ?